Tacabrutideg's safety profile was tolerable, and the drug had antitumor activity in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies.
Investigating Tacbrutideg in CLL/SLL and Other B-Cell Malignancies
Advertisement
Advertisement
Trending on OncLive
1
From Ovarian to Endometrial Cancer, Experts Spotlight Standout Data From ASCO 2026
2
Gilteritinib Yields Comparable Efficacy vs Midostaurin in Newly Diagnosed FLT3-Mutated AML but Fails to Meet Phase 3 Primary End Point
3
Tuspetinib Plus Venetoclax and Azacitidine Is Safe and Effective Across Molecular Subgroups in Newly Diagnosed AML
4
Tacabrutideg Drives Responses in Heavily Pretreated CLL/SLL
5